One of the primary mechanisms of resistance and treatment failure in CML is the acquisition of BCR–ABL1 mutations that render the fusion protein completely or relatively unresponsive to TKIs. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.